As the World Health Organization (WHO) marked April 6 as World Health Day, the
United Nations agency charged with directing and coordinating authority on health matters called for “urgent and concerted action” by governments, industry
and society to slow down the spread of drug resistance.
Takeda Pharmaceutical Co. and Heptares Therapeutics on April 11 announced the formation of a two-year drug discovery collaboration focused on a
single G-protein coupled receptor (GPCR) that plays an important role in the pathology of central nervous system disorders.
BioTime Inc., a
biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, and XenneX Inc., a biomedical research tool
provider, recently announced the formation of LifeMap Sciences Inc., a joint effort that plans to make available a database for use by stem cell
PGXL Laboratories, a provider of pharmacogenetic testing and interpretive services, recently announced that it has established a
collaborative partnership with AutoGenomics Inc., a developer of an automated, microarray-based multiplexing diagnostic platform, wherein they will utilize
this platform—the automated INFINITI analyzer—for several different personalized medicine applications.
By facilitating personalized healthcare, molecular techniques have the potential to significantly improve patient care,
rescue effective drugs from development failure and provide cost benefits to both healthcare systems and pharma development programs.
In a decision rendered just hours
before we put our May issue to bed, the U.S. Court of Appeals for the District of Columbia crowned the Obama Administration the victor in an ongoing debate
over whether the U.S. government should help fund research that involves the destruction of embryos. Read on for the latest in the controversial Sherley v.